Novo Nordisk news in 2026: 25 dated events
The latest Novo Nordisk event on this page is dated Oct 28, 2026. qz.com reported: New weight-loss drugs: what 6 drugmakers are testing.
PublicPharmaceutical Manufacturing10,000+ employeesnovonordisk.comLinkedIn
Get Novo Nordisk's live signals in Claude or ChatGPT, or by API
What changed at Novo Nordisk this week? Use Autobound signals for novonordisk.com.- Dated events
- 25
- Last 90 days
- 25
- Latest
- Oct 28, 2026
Source: Autobound Signal API · 93 signals tracked for Novo Nordisk · updated
News · latest 10
Latest Novo Nordisk news
Showing 10 of 25 dated events. The Signal API returns all of them.
Get them with one API call- New weight-loss drugs: what 6 drugmakers are testingNovo Nordisk is developing CagriSema and amycretin as new weight-loss drugs.
- Novo Nordisk Faces a Three-Part Test: Doctor Data Questions, a Pediatric Insulin Approval and a BuybNovo Nordisk suffered a cyberattack that exposed an internal directory classifying healthcare professionals by prescription likelihood and familiarity with its drugs.
- Podiatrist let unlicensed salesman perform surgery, then billed Medicare; Novo Nordisk partners with OpenAI to accelerate drug development; a better predictor of hypertension...Novo Nordisk has partnered with OpenAI to deploy artificial intelligence across its research, manufacturing, supply chain, and commercial operations.
- Novo Nordisk Buys Time With Nanexa Deal and US Job Cuts as Shares Stay Under PressureWith Jiangsu Hengrui Pharmaceuticals
- Novo provides update on the denecimig Biologics License Application (BLA) in the USNovo Nordisk is developing denecimig, a treatment for haemophilia A, and aims to launch it in the US in the first half of 2027, pending regulatory approval.
- Novo’s Wegovy® (semaglutide) reduced liver fat to normal levels in 9 out of 10 adults with obesity and excess liver fatNovo Nordisk is evaluating the effect of its once-weekly injectable semaglutide 2.4 mg in people with MASH and moderate to advanced liver fibrosis in its ongoing phase 3 ESSENCE trial, with results from the second part expected in 2029.
- Novo’s investigational obesity and diabetes drug CagriSema reduces ‘food noise’ and shows benefits in organ and bone healthWith European Association for the Study of Diabetes
- Semaglutide 2 mg Escalation Tied to Lower MACE vs Tirzepatide Switch in T2DNovo Nordisk released a retrospective US claims analysis showing that adults with type 2 diabetes who escalated semaglutide from 1 mg to 2 mg had a 6% lower adjusted MACE risk than those who switched to tirzepatide.
- Novo Nordisk agrees to buy Chinese weight-loss pill for 2.5 billion eurosWith Jiangsu Hengrui Pharmaceuticals
- Novo and Hengrui Pharma enter exclusive license agreement for once-weekly oral GLP-1/GIP dual receptor agonist HRS-1596Novo Nordisk has entered into an exclusive license agreement with Hengrui Pharma for HRS-1596, a phase 1-ready GLP-1/GIP dual receptor agonist, in a deal potentially worth up to $2.6 billion.
Showing 10 of 25 dated events. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Novo Nordisk with the Signal API
One POST /v1/companies/enrich call with novonordisk.com returns Novo Nordisk news signals (news), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"novonordisk.com","signal_types":["news"],"limit":20}'Bulk data
Need this signal for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real News records, as a CSV.
Same industry
News at related companies
Questions about Novo Nordisk news
What is the latest news on Novo Nordisk?
What is going on with Novo Nordisk?
Page updated , the date of the newest row on this page.
Source. News articles about the company, one source link per event.
Method. Stories about the same event within 14 days merge into one row. Noise (lists, stock tips, recaps) is removed.
Data as of .